Trial · NCT00000134
Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)
NCT00000134, Phase 3, Completed, Johns Hopkins Bloomberg School of Public Health; results first posted 2015-09-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT). Trials, record NCT00000134. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00000134
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)
- NCT number
- NCT00000134
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 279 participants, actual
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Conditions
- HIV Infections, Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
- Interventions
- Ganciclovir, Foscarnet
- First posted
- 1999-09-24
- Last updated
- 2015-09-14
- Results first posted
- 2015-09-14
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Morbidity | Patients will be seen at baseline, monthly for six months, and then every three months until death or termination of the trial | To determine the best therapeutic regimen, using currently approved drugs, for treatment of relapsed cytomegalovirus (CMV) retinitis. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Morbidity | Patients will be seen at baseline, monthly for six months, and then every three months until death or termination of the trial | participants | NUMBER |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Morbidity | Intravenous Foscarnet | 88 | participants | ||
| Morbidity | Intravenous Ganciclovir | 93 | participants | ||
| Morbidity | Combination Therapy | 93 | participants |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Intravenous Foscarnet | 89 | |
| Overall Study | STARTED | Intravenous Ganciclovir | 94 | |
| Overall Study | STARTED | Combination Therapy | 96 | |
| Overall Study | COMPLETED | Intravenous Foscarnet | 89 | |
| Overall Study | COMPLETED | Intravenous Ganciclovir | 94 | |
| Overall Study | COMPLETED | Combination Therapy | 96 | |
| Overall Study | NOT COMPLETED | Intravenous Foscarnet | 0 | |
| Overall Study | NOT COMPLETED | Intravenous Ganciclovir | 0 | |
| Overall Study | NOT COMPLETED | Combination Therapy | 0 |
Source ClinicalTrials.gov
Adverse events9
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hospitalizations | Infections and infestations | Intravenous Foscarnet | 7 | 88 | 9 |
| other | Hospitalizations | Infections and infestations | Intravenous Ganciclovir | 7 | 93 | 10 |
| other | Hospitalizations | Infections and infestations | Combination Therapy | 10 | 93 | 11 |
| serious | Neutropenia | Blood and lymphatic system disorders | Intravenous Foscarnet | 32 | 88 | 86 |
| serious | Neutropenia | Blood and lymphatic system disorders | Intravenous Ganciclovir | 41 | 93 | 95 |
| serious | Neutropenia | Blood and lymphatic system disorders | Combination Therapy | 51 | 93 | 107 |
| serious | Thrombocytopenia | Blood and lymphatic system disorders | Intravenous Foscarnet | 14 | 88 | 28 |
| serious | Thrombocytopenia | Blood and lymphatic system disorders | Intravenous Ganciclovir | 8 | 93 | 19 |
| serious | Thrombocytopenia | Blood and lymphatic system disorders | Combination Therapy | 15 | 93 | 40 |
Source ClinicalTrials.gov
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Intravenous Foscarnet | ||
| Total, all-cause mortality | Intravenous Ganciclovir | ||
| Total, all-cause mortality | Combination Therapy | ||
| Total, other adverse events | Intravenous Foscarnet | 7 | 88 |
| Total, other adverse events | Intravenous Ganciclovir | 7 | 93 |
| Total, other adverse events | Combination Therapy | 10 | 93 |
| Total, serious adverse events | Intravenous Foscarnet | 32 | 88 |
| Total, serious adverse events | Intravenous Ganciclovir | 41 | 93 |
| Total, serious adverse events | Combination Therapy | 51 | 93 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants2
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| U10EY008057 | Studies of Ocular Complications of AIDS - Coordinating Center | VAN NATTA, MARK L | JOHNS HOPKINS UNIVERSITY | NATIONAL EYE INSTITUTE | 1988 to 2012 | NIH RePORTER |
| U01AI027668 | JOHNS HOPKINS ADULT AIDS CLINICAL TRIALS UNIT | FLEXNER, CHARLES W. | JOHNS HOPKINS UNIVERSITY | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES | 1988 to 2006 | NIH RePORTER |
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00000134
GET https://conductscience.org/api/trials/v1/NCT00000134/registered